WO1997039721A3 - Methods and compositions for regulating t cell subsets by modulating transcription factor activity - Google Patents

Methods and compositions for regulating t cell subsets by modulating transcription factor activity Download PDF

Info

Publication number
WO1997039721A3
WO1997039721A3 PCT/US1997/006708 US9706708W WO9739721A3 WO 1997039721 A3 WO1997039721 A3 WO 1997039721A3 US 9706708 W US9706708 W US 9706708W WO 9739721 A3 WO9739721 A3 WO 9739721A3
Authority
WO
WIPO (PCT)
Prior art keywords
nip45
protein
methods
maf
modulated
Prior art date
Application number
PCT/US1997/006708
Other languages
French (fr)
Other versions
WO1997039721A2 (en
Inventor
Laurie H Glimcher
Martin R Hodge
I-Cheng Ho
Original Assignee
Harvard College
Laurie H Glimcher
Martin R Hodge
Ho I Cheng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/636,602 external-priority patent/US5958671A/en
Priority claimed from US08/755,592 external-priority patent/US6537810B1/en
Priority claimed from US08/755,584 external-priority patent/US5858711A/en
Application filed by Harvard College, Laurie H Glimcher, Martin R Hodge, Ho I Cheng filed Critical Harvard College
Priority to JP09538278A priority Critical patent/JP2000510333A/en
Priority to CA002252643A priority patent/CA2252643A1/en
Priority to EP97926377A priority patent/EP0891425A2/en
Priority to AU31155/97A priority patent/AU720455B2/en
Priority to NZ332897A priority patent/NZ332897A/en
Publication of WO1997039721A2 publication Critical patent/WO1997039721A2/en
Publication of WO1997039721A3 publication Critical patent/WO1997039721A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Methods for modulating production of a T helper type 2 (Th2)-associated cytokine, in particular interleukin-4, by modulating the activity of one or more transcription factors that cooperate with NF-AT family proteins to regulate expression of a Th2-associated cytokine gene are disclosed. In one embodiment, the activity of a maf family protein (e.g., c-Maf or a small maf protein, such as p18) is modulated. In another embodiment, the activity of a protein that interacts with an NF-AT family protein (e.g., NIP45) is modulated. Combination methods, for example wherein the activities of a maf family protein and an NF-AT protein are modulated or the activities of a maf protein and an NF-AT-interacting protein are modulated, are also encompassed by the invention. Methods for modulating development of T helper type 1 (Th1) or T helper type 2 (Th2) subsets in a subject using agents that modulate transcription factor activity are also disclosed. NIP45 compositions, including isolated nucleic acid molecules encoding NIP45, antisense nucleic acid molecules, recombinant expression vectors containing a NIP45 nucleic acid molecule, host cells into which such expression vectors have been introduced and non-human transgenic animals carrying a NIP45 transgene, are also provided by the invention. The invention further provides isolated NIP45 proteins and peptides, NIP45 fusion proteins and anti-NIP45 antibodies. Methods of using the NIP45 compositions of the invention are also disclosed.
PCT/US1997/006708 1996-04-23 1997-04-23 Methods and compositions for regulating t cell subsets by modulating transcription factor activity WO1997039721A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP09538278A JP2000510333A (en) 1996-04-23 1997-04-23 Methods and compositions for controlling T cell subsets by modulating factor activity
CA002252643A CA2252643A1 (en) 1996-04-23 1997-04-23 Methods and compositions for regulating t cell subsets by modulating transcription factor activity
EP97926377A EP0891425A2 (en) 1996-04-23 1997-04-23 Methods and compositions for regulating t cell subsets by modulating transcription factor activity
AU31155/97A AU720455B2 (en) 1996-04-23 1997-04-23 Methods and compositions for regulating T cell subsets by modulating transcription factor activity
NZ332897A NZ332897A (en) 1996-04-23 1997-04-23 Methods and compositions for modulating production of a T helper type 2 (Th2)-associated cytokine by regulating transcription factor activity in association with a Nuclear Factor of Activated T cells (NF-AT) protein

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/636,602 US5958671A (en) 1996-04-23 1996-04-23 Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US08/636,602 1996-04-23
US08/755,592 US6537810B1 (en) 1996-04-23 1996-11-25 Methods for regulating T cell subsets by modulating transcription factor activity
US08/755,584 1996-11-25
US08/755,592 1996-11-25
US08/755,584 US5858711A (en) 1996-11-25 1996-11-25 NF-AT-interacting protein NIP45 and methods of use therefor

Publications (2)

Publication Number Publication Date
WO1997039721A2 WO1997039721A2 (en) 1997-10-30
WO1997039721A3 true WO1997039721A3 (en) 1998-04-09

Family

ID=27417596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/006708 WO1997039721A2 (en) 1996-04-23 1997-04-23 Methods and compositions for regulating t cell subsets by modulating transcription factor activity

Country Status (8)

Country Link
EP (1) EP0891425A2 (en)
JP (1) JP2000510333A (en)
KR (1) KR20000010606A (en)
CN (1) CN1225682A (en)
AU (1) AU720455B2 (en)
CA (1) CA2252643A1 (en)
NZ (1) NZ332897A (en)
WO (1) WO1997039721A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722388D0 (en) * 1997-10-24 1997-12-24 Zeneca Ltd NIP45 human homolog
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
AU4219899A (en) 1998-05-28 1999-12-13 President And Fellows Of Harvard College Methods and compositions relating to modulation of cartilage cell growth and/or differentiation by modulation of nfatp activity
ES2283340T3 (en) 1999-12-30 2007-11-01 President And Fellows Of Harvard College METHODS CONCERNING THE MODULATION OF THE ACTIVITY OF THE TH2 CELL SUBCONJUNCT BY MODULATION OF THE ACTIVITY OF XBP-1.
AU3279301A (en) * 2000-01-11 2001-07-24 Maxygen, Inc. Monocyte-derived dendritic cell subsets
ES2272471T3 (en) * 2000-04-25 2007-05-01 Bayer Healthcare Ag REGULATION OF A PROTEIN VARIANT NIP45 THAT INTERACTS WITH NF-AT.
AU2001290316A1 (en) * 2000-10-02 2002-04-15 Mochida Pharmaceutical Co., Ltd. Gata-3 expression inhibitor and method of screening the same
JP2004537506A (en) 2001-03-01 2004-12-16 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド Use of certain steroids to treat blood cell deficiency
US20050079496A1 (en) * 2001-08-17 2005-04-14 Edgar Serfling Methods for diagnosing and treating neoplasias using nf-at transcriptions factors
IL147138A0 (en) 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
JP5161798B2 (en) * 2006-03-02 2013-03-13 アンチトープ リミテッド T cell assay
US8227184B2 (en) 2008-01-14 2012-07-24 President And Fellows Of Harvard College Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity
KR101146335B1 (en) * 2009-10-12 2012-05-21 한국원자력의학원 TRANSGENIC MOUSE EXPRESSING REPORTER PROTEIN UNDER REGULATION OF α-FETOPROTEIN ENHANCER AND PROMOTER, METHOD FOR PREPARATION THEREOF AND METHOD FOR SCREENING COMPOUNDS INDUCING INCREASE OR DECREASE OF Α-FETOPROTEIN EXPRESSION USING THE SAME
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
WO2013134774A1 (en) 2012-03-09 2013-09-12 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
WO2015019125A1 (en) 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
CASOLARO V ET AL: "Inhibition of NF -AT-dependent transcription by NF -kappa B: implications for differential gene expression in T helper cell subsets.", PROC. NATL. ACAD. SCI. USA, vol. 92, December 1995 (1995-12-01), pages 11623 - 11627, XP002045455 *
CASOLARO V ET AL: "Molecular mechanisms of interleukin-4 production", INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY, vol. 10, no. 2, Supplement, 1997, pages 1 - 5, XP002045467 *
FRANCASTEL C ET AL: "c-Jun inhibits NF-E2 transcriptional activity in association with p18/maf in Friend erythroleukemia cells.", ONCOGENE, vol. 14, 1997, pages 873 - 877, XP002045461 *
HO I-C ET AL: "The proto-oncogene c - maf is responsible for tissue-specific expression of interleukin-4.", CELL 85 (7). 1996. 973-983. ISSN: 0092-8674, 28 June 1996 (1996-06-28), XP002045459 *
HODGE M R ET AL: "NF-AT-driven interleukin-4 transcription potentiated by NIP45.", SCIENCE (WASHINGTON D C) 274 (5294). 1996. 1903-1905. ISSN: 0036-8075, 13 December 1996 (1996-12-13), XP002045448 *
HODGE M R ET AL: "The proximal promoter of the IL - 4 gene is composed of multiple essential regulatory sites that bind at least two distinct factors.", JOURNAL OF IMMUNOLOGY 154 (12). 1995. 6397-6405. ISSN: 0022-1767, vol. 154, no. 12, 1995, pages 6397 - 6405, XP002045451 *
HODGE M. R. ET AL: "Hyperproliferation and dysregulation of IL-4 expression in NF-ATp-deficient mice", IMMUNITY, vol. 4, April 1996 (1996-04-01), pages 397 - 405, XP002045449 *
IGARASHI K ET AL: "Activity and expression of murine small Maf family protein MafK.", JOURNAL OF BIOLOGICAL CHEMISTRY 270 (13). 1995. 7615-7624. ISSN: 0021-9258, XP002045548 *
K. IGARASHI ET AL.: "Conditional expression of the ubiquitous transcription factor MafK induces erythroleukemia cell differentiation.", PROC. NATL. ACAD. SCI. USA., vol. 92, August 1995 (1995-08-01), pages 7445 - 7449, XP002055948 *
K. KATAOKA ET AL.: "MafB, a new maf family transcription activator that can associate with Maf and Fos but not with Jun.", MOLECULAR AND CELLULAR BIOLOGY, vol. 14, no. 11, November 1994 (1994-11-01), pages 7581 - 7591, XP002055947 *
K. KATAOKA ET AL.: "Small Maf proteins heterodimerize with Fos and may act as competitive repressors of the NF-E2 transcription factor.", MOLECULAR AND CELLULAR BIOLOGY, vol. 15, no. 4, April 1995 (1995-04-01), pages 2180 - 2190, XP002055946 *
KURSCHNER C ET AL: "The maf proto-oncogene stimulates transcription from multiple sites in a promoter that directs Purkinje neuron-specific gene expression.", MOLECULAR AND CELLULAR BIOLOGY 15 (1). 1995. 246-254. ISSN: 0270-7306, XP002045549 *
M.H. SIEWEKE ET AL.: "MafB represses erythroid gene and differentiation through direct interaction with c-Ets-1", LEUKEMIA, vol. 11, no. 3, April 1997 (1997-04-01), pages 486 - 488, XP002055949 *
PELTZ, GARY: "Transcription factors in immune-mediated disease", CURR. OPIN. BIOTECHNOL. (1997), 8(4), 467-473 CODEN: CUOBE3;ISSN: 0958-1669, XP002045460 *
ROONEY J W ET AL: "A common factor regulates both Th1- and Th2 -specific cytokine gene expression.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL 13 (3). 1994. 625-633. ISSN: 0261-4189, XP002045452 *
ROONEY J W ET AL: "Coordinate and cooperative roles for NF -AT and AP-1 in the regulation of the murine IL - 4 gene.", IMMUNITY, vol. 2, May 1995 (1995-05-01), pages 473 - 483, XP002045450 *
TARA, DAVID ET AL: "Characterization of the constitutive and inducible components of a T cell IL - 4 activation responsive element", J. IMMUNOL. (1995), 154(9), 4592-602 CODEN: JOIMA3;ISSN: 0022-1767, XP002045456 *
WIERENGA E A ET AL: "Reduced NF -AT binding at the IL - 4 -CLE0. element in TH2 cells of atopic patients.", 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY. THE 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY;MEETING SPONSORED BY THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS AND THE INTERNATIONAL UNION OF IMMUNOLOGICAL SOCIETIES, SAN FRANCISCO, CALIFORNIA, USA, JULY 23-29,, XP002045458 *

Also Published As

Publication number Publication date
WO1997039721A2 (en) 1997-10-30
AU720455B2 (en) 2000-06-01
CA2252643A1 (en) 1997-10-30
EP0891425A2 (en) 1999-01-20
CN1225682A (en) 1999-08-11
AU3115597A (en) 1997-11-12
KR20000010606A (en) 2000-02-15
JP2000510333A (en) 2000-08-15
NZ332897A (en) 2000-04-28

Similar Documents

Publication Publication Date Title
WO1997039721A3 (en) Methods and compositions for regulating t cell subsets by modulating transcription factor activity
WO1999043808A8 (en) Human c-maf compositions and methods of use thereof
AU7599500A (en) Novel gl50 molecules and uses therefor
EP1798239A3 (en) G-protein coupled receptors and uses therefor
DK0941318T3 (en) Dumbbell-shaped gene expression expression systems
NO20020861L (en) New B7-4 molecules and uses thereof
CA2208013A1 (en) Recombinant dna molecules and expression vectors for erythropoietin
AP9901542A0 (en) DNA encoding lepidopteran-active delta-endotoxins and its use.
WO2001038357A3 (en) Jaffa, a novel fibroblast growth factor family member and uses therefor
AU3217100A (en) Methods of use of a novel lysyl oxidase-related protein
DE60144021D1 (en) FOR CELL CYCLE PROTEINS CODING NUCLEIC ACID AND ITS USE
WO1999047686A3 (en) Human mekk proteins, corresponding nucleic acid molecules, and uses therefor
WO2000075358A3 (en) Mammalian toll homologues and uses thereof
WO2001073028A3 (en) A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
AU2002211446A1 (en) 32144, a human fatty acid amide hydrolase and uses thereof
DK1183355T3 (en) T-BET preparations and methods for their preparation
NO20012471L (en) Potassium channel interactors and uses thereof
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
WO2001075076A3 (en) 33167, a novel human hydrolase and uses therefor
WO2001068857A3 (en) 18615 and 48003, human ion channels and uses therefor
AU2002234132A1 (en) 13245, a novel human myotonic dystrophy type protein kinase and uses therefor
WO2002040655A3 (en) Phospholipase a2 group preferentially expressed in th2 cells
MXPA03002557A (en) Potassium channel interactors and uses therefor.
AU2001253258A1 (en) Human trp-like calcium channel protein-2 (tlcc-2)
ATA282386A (en) METHOD FOR EXPRESSING GENES IN YEAST AND DNA FRAGMENTS AND PLASMIDES CONTAINING THESE DNA FRAGMENTS FOR USE IN THIS METHOD

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97195740.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US US US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2252643

Country of ref document: CA

Ref document number: 2252643

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019980708492

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1997926377

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 332897

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1997926377

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019980708492

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019980708492

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997926377

Country of ref document: EP